From Healthing: "The body responsible for pricing patented drugs in Canada — the Patented Medicine Prices Review Board (PMPRB) — has proposed changes to lower the cost of drugs, which are scheduled to come into [...]
From C.A.R.P.: "Like father, like son. In the 1970s, Trudeau senior brought in price controls to combat inflation. They failed miserably. On July 1, Trudeau junior’s government will activate new Patented Medicines Price Review Board [...]
From The Ottawa Citizen: "The federal Patented Medicines Price Review Board thinks companies would be happy to sell Canada their new drugs for much less than they get in many other 36 OECD countries. It [...]
May 11, 2021 The Right Honourable Justin Trudeau, P.C., M.P. Prime Minister of Canada 80 Wellington St. Ottawa, ON, K1A 0A2 Subject: Delay and reconsider the PMPRB regulations Dear Prime Minister Trudeau, I am [...]
As we battle the pandemic, we should remember that cancer kills 7,000 Canadians every month and put the same effort into reducing that sad toll. In the three months since COVID-19 started shutting down the [...]
Background Canada has an established publicly funded health care system with a complex drug approval and funding process. After proof of efficacy (POE; key publication/presentation) and before becoming publicly accessible, each drug undergoes a Health [...]
It takes on average 6–12 years to develop new anticancer drugs from discovery to approval. Effective new agents prolong survival. To demonstrate the importance of rapid drug approval, we calculated life-years potentially saved if selected agents [...]
Cancer research in the United States: A critical review of current status and proposal for alternative models
This commentary reviews the evolution of the process of cancer research in the United States over the past 6 decades, from an academic-based to drug industry-based research, and the advantages and concerns. It proposes a [...]
The Urgent Need for Clinical Research Reform to Permit Faster, Less Expensive Access to New Therapies for Lethal Diseases
High costs of complying with drug development regulations slow progress and contribute to high drug prices and, hence, mounting health care costs...
Interesting new research suggests that the burden of proof required by Canada’s health technology assessment (HTA) process for new drugs is too rigid and unfairly excludes many treatments for rare disorders from public drug insurance coverage...